The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Estimated Market Size Of The Iron Deficiency Anemia Therapy Market During 2026–2030?
The iron deficiency anemia therapy market has demonstrated strong growth over recent years. Its value is set to rise from $4.78 billion in 2025 to $5.15 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. The expansion observed in the past can be attributed to the increasing occurrence of iron deficiency anemia, heightened awareness regarding anemia management, the proliferation of hospital-based treatment approaches, the rising adoption of oral iron supplements, and advancements in diagnostic screening for anemia.
The iron deficiency anemia therapy market is anticipated to show significant expansion over the next few years. It is predicted to reach a value of **$6.92 billion by 2030, progressing at a compound annual growth rate (CAGR) of 7.6%**. This growth during the forecast period is propelled by the escalating demand for rapid anemia correction, the increasing occurrence of chronic conditions that cause anemia, the proliferation of specialized anemia clinics, a rising focus on maternal and pediatric anemia care, and ongoing advancements in iron formulation technologies. Prominent trends expected in this period include the wider acceptance of intravenous iron therapies, a growing need for targeted anemia treatments, an intensified focus on customized patient therapy regimens, the development of more oral and parenteral combination therapies, and an increased emphasis on treatment efficacy and safety.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24265&type=smp
Which Economic Or Industry Drivers Are Impacting The Iron Deficiency Anemia Therapy Market?
The rising prevalence of chronic diseases is anticipated to drive the expansion of the iron deficiency anemia therapy market moving forward. Chronic diseases are defined as long-term medical conditions that typically last for a year or more. This increase in chronic illnesses can be attributed to the growing incidence of unhealthy lifestyles, including poor diet, lack of physical activity, and smoking, which contribute to conditions such as obesity, diabetes, and heart disease, resulting in prolonged health complications. Chronic conditions can heighten the demand for iron deficiency anemia therapy by impairing the body’s proper iron absorption, thereby elevating the risk of iron deficiency and necessitating supplementation or medical intervention to restore iron levels. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a GP were diagnosed with non-diabetic hyperglycemia in 2023, or pre-diabetes, marking an 18% increase from 3,065,825 cases in 2022. Consequently, the increasing cases of chronic diseases are propelling growth in the iron deficiency anemia therapy market.
How Are The Various Segments Of The Iron Deficiency Anemia Therapy Market Categorized?
The iron deficiency anemia therapy market covered in this report is segmented –
1) By Product Type: Ferrous Sulphate, Ferrous Gluconate, Ferrous Fumerate, Ferric Hydroxide
2) By Therapy Type: Parenteral Iron Therapy, Oral Iron Therapy, Red Blood Cell Transfusion, Other Therapy Types
3) By Therapy Areas: Inflammatory Bowel Diseases, Renal Diseases, Obstetrics and Gynecology, Congestive Heart Failure, Oncology
4) By Distribution channel: Hospital Pharmacy, Drug Stores And Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Speciality Clinics, Home Care Setting, Other End Users
Subsegments:
1) By Ferrous Sulphate: Oral Ferrous Sulphate Tablets, Oral Liquid Ferrous Sulphate, Intravenous Ferrous Sulphate, Extended Or Delayed Release Formulations
2) By Ferrous Gluconate: Oral Tablets, Chewable Tablets, Liquid Solutions, Pediatric Formulations
3) By Ferrous Fumarate: Oral Tablets Or Capsules, Prenatal Supplements, Multivitamin with Iron Formulations, Pediatric Drops Or Syrups
4) By Ferric Hydroxide: Intravenous Iron Therapy, Ferric Hydroxide Polymaltose Complex, Dialysis-Specific Iron Therapy, Hospital-Based Injectable Formulations
What Trends Are Affecting The Expansion Of The Iron Deficiency Anemia Therapy Market?
Leading companies in the iron deficiency anemia therapy market are concentrating on advancing treatment methods, particularly through injectable formulations, to boost effectiveness and availability. An injectable formulation is defined as a recently developed or altered medication designed for administration through injection. For example, in May 2023, Emcure Pharmaceuticals Ltd., an Indian pharmaceutical firm, introduced Orofer FCM 750. This product is a ferric carboxymaltose (FCM) formulation intended for treating both iron deficiency and iron deficiency anemia (IDA). Key advantages include better patient adherence, as it requires less frequent dosing than oral supplements. Its primary goal is to provide effective treatment for iron deficiency anemia, particularly for patients unable to tolerate oral iron. This 750 mg/15 ml injectable ferric carboxymaltose received approval from India’s DCGI for treating iron deficiency anemia (IDA) in patients who do not respond to oral iron. It is particularly recommended for pregnant women with hemoglobin <10 g/dl and weight 35–70 kg, providing a 15-minute infusion (when diluted in saline) and aligning with Anemia Mukt Bharat guidelines as a first-line therapy for severe instances.
Which Major Firms Influence Developments In The Iron Deficiency Anemia Therapy Market?
Major companies operating in the iron deficiency anemia therapy market are Sanofi SA, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, CSL Vifor AG, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Luitpold Pharmaceuticals Inc., Covis Pharma GmbH, Pharmacosmos Therapeutics Inc., AFT Pharmaceuticals Ltd., Rockwell Medical Inc., Otsuka Pharmaceutical Co. Ltd., AdvaCare Pharma USA LLC, Apotex Inc., KYE Pharmaceuticals Inc., Emcure Pharmaceuticals Limited, Shield Therapeutics plc, Abbott Laboratories, Bayer AG, Pfizer Inc., Lupin Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd.
Read the full iron deficiency anemia therapy market report here:
What Are The Top-Performing Regions Within The Iron Deficiency Anemia Therapy Market?
North America was the largest region in the iron deficiency anemia therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the iron deficiency anemia therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Iron Deficiency Anemia Therapy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24265&type=smp
Browse Through More Reports Similar to the Global Iron Deficiency Anemia Therapy Market 2026, By The Business Research Company
Hemochromatosis Iron Overload Disease Treatment Market Report 2026
Anemia And Other Blood Disorder Drugs Market Report 2026
Chemotherapy Induced Anemia Market Report 2026
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model